Full text is available at the source.
Abstract
No direct head-to-head trials compare tirzepatide and dulaglutide in heart failure with preserved ejection fraction (HFpEF).
- Tirzepatide is associated with superior weight loss compared to dulaglutide.
- Recent trials, such as SURPASS-CVOT, suggest potential cardiovascular benefits of tirzepatide.
- The lack of direct comparisons limits understanding of the relative effectiveness of these treatments in HFpEF.
Simplified